CTCBIO Inc (060590) Fair Value & Analysis
Healthcare · KR · Market cap 77.8B KRW
Fair value as of: Jun 24, 2026
Analysis
CTCBIO Inc (060590) currently trades at 2,980 KRW, while our model-based Fair Value estimate is 2,931 KRW — implying the stock looks roughly 1.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CTCBIO Inc (060590) undervalued?
What is the fair value of 060590?
What is the quality score of 060590?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.